Soft tissue sarcoma
View article: Figure S2 from Interdependence of SS18-SSX–driven YAP1 and β-Catenin Activation in Synovial Sarcoma
Figure S2 from Interdependence of SS18-SSX–driven YAP1 and β-Catenin Activation in Synovial Sarcoma Open
Figure S2 shows that inhibition of YAP1, TAZ or β-catenin via siRNA-mediated knockdown or inhibitor treatment reduces each other's transcriptional activity.
View article: Figure S5 from Interdependence of SS18-SSX–driven YAP1 and β-Catenin Activation in Synovial Sarcoma
Figure S5 from Interdependence of SS18-SSX–driven YAP1 and β-Catenin Activation in Synovial Sarcoma Open
Figure S5 shows that there is no interdependency between YAP1/TAZ and β-catenin activation in control cell lines.
View article: Carbon Ion Radiotherapy for Unresectable Primary or Recurrent Soft Tissue Sarcomas: Long-Term Outcomes based on the Local Effect Model System
Carbon Ion Radiotherapy for Unresectable Primary or Recurrent Soft Tissue Sarcomas: Long-Term Outcomes based on the Local Effect Model System Open
Background The application of carbon ion radiotherapy (CIRT) for unresectable primary or recurrent soft tissue sarcoma (STS) remains controversial and existing data are limited. We herein present our institutional experience with CIRT for …
View article: ATRX Loss Predicts Poor Outcomes and Reveals a Therapeutic Vulnerability to TEAD Inhibition in Soft Tissue Sarcomas
ATRX Loss Predicts Poor Outcomes and Reveals a Therapeutic Vulnerability to TEAD Inhibition in Soft Tissue Sarcomas Open
ATRX is one of the most frequently altered genes in sarcoma and encodes an ATP-dependent chromatin remodeler implicated in maintaining heterochromatin. However, ATRX alterations have not been leveraged for sarcoma treatment. We observed lo…
View article: Software for Therapy Response Prediction in Patients with Metastatic Soft Tissue Sarcomas Using CT based Delta Radiomics
Software for Therapy Response Prediction in Patients with Metastatic Soft Tissue Sarcomas Using CT based Delta Radiomics Open
Release for submission
View article: Challenges and Progress for Treatment of Malignant Peripheral Nerve Sheath Tumors in the Context of Recent Successes for Sarcoma Therapy
Challenges and Progress for Treatment of Malignant Peripheral Nerve Sheath Tumors in the Context of Recent Successes for Sarcoma Therapy Open
Malignant peripheral nerve sheath tumors (MPNSTs) are one of the most difficult sarcomas to treat. Due to the rarity of MPNSTs, many of the therapeutic approaches used are from treatment guidelines for soft tissue sarcoma. Besides surgery,…
View article: Ethmoidal–nasal alveolar rhabdomyosarcoma in an adolescent: The contribution of radiotherapy in a high-risk case
Ethmoidal–nasal alveolar rhabdomyosarcoma in an adolescent: The contribution of radiotherapy in a high-risk case Open
Alveolar rhabdomyosarcoma (ARMS), a histological subtype associated with a poorer prognosis, represents an aggressive form of the disease. In the ethmoidal–nasal region, the proximity of critical structures such as the orbit and the skull …
View article: Supplementary Figure S5 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Supplementary Figure S5 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma Open
Supplementary Figure S5. Characteristics of prognosis-related ceRNA network.
View article: Favourable outcomes of extraskeletal Ewing sarcoma treated on a non-dense chemotherapy backbone with inclusion of radiotherapy for local control
Favourable outcomes of extraskeletal Ewing sarcoma treated on a non-dense chemotherapy backbone with inclusion of radiotherapy for local control Open
View article: Table S4 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma
Table S4 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma Open
Table S4: Representativeness of Study Participants.
View article: Supplementary Figure S5 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Supplementary Figure S5 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma Open
Supplementary Figure 5. Overall survival of historical MPM cohorts
View article: Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma Open
CONSORT diagram
View article: DEFINITIVE PENCIL BEAM SCANNING CARBON ION RADIOTHERAPY FOR THORACIC BONE AND SOFT TISSUE SARCOMA
DEFINITIVE PENCIL BEAM SCANNING CARBON ION RADIOTHERAPY FOR THORACIC BONE AND SOFT TISSUE SARCOMA Open
View article: supplementary table 1 from Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA
supplementary table 1 from Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA Open
supplementary table
View article: Table S2 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma
Table S2 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma Open
Table S2: Dose reduction, delay, and omission due to AE.
View article: Supplementary Fig. 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
Supplementary Fig. 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis Open
Supplementary Fig. 1
View article: Imaging-driven diagnosis of retroperitoneal psoas major alveolar soft part sarcoma: a case report
Imaging-driven diagnosis of retroperitoneal psoas major alveolar soft part sarcoma: a case report Open
Alveolar soft part sarcoma (ASPS) is an infrequent and malignant soft tissue tumor with an elusive tissue origin. Its occurrence in the retroperitoneal psoas major muscle is extremely rare. The tumor’s deep retroperitoneal location, comple…
View article: Table S1 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma
Table S1 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma Open
Table S1: DLT exceptions.
View article: Supplementary Figure S7 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Supplementary Figure S7 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma Open
Supplementary Figure S7. Investigation of therapeutic effects of TSA on SARC.
View article: Supplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
Supplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101) Open
Treemap of most common drug mechanisms for patients treated in biomarker-matched studies.
View article: Supplementary Table S17 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma
Supplementary Table S17 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma Open
Supplementary Table S17. CD4+/CD8+ T cells infiltration levels in tumor tissues of mice bearing with S180.
View article: Table S3 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma
Table S3 from Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma Open
Table S3: Pharmacokinetic parameters after a 60-minute IV infusion of olaratumab on Day 1 and Day 8 of Cycle 1 and Cycle 3 with pembrolizumab.
View article: Supplementary Material and Methods S1 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Supplementary Material and Methods S1 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma Open
Materials and methods for in vivo toxicity and cellular fluorescence assays
View article: Table S1 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
Table S1 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition Open
Patient tumor information
View article: How rare is too rare to suspect? A case of a well-differentiated liposarcoma of the piriform recess of the larynx
How rare is too rare to suspect? A case of a well-differentiated liposarcoma of the piriform recess of the larynx Open
Liposarcomas are among the rarest soft tissue sarcomas in the larynx, accounting for less than 1% of cases with the piriform recess of the larynx being one of the least common sites. These tumors present significant diagnostic delays due t…
View article: Supplementary Table S1 from A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma
Supplementary Table S1 from A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma Open
Representativeness of Study Participants
View article: SMARCB1 (INI-1) deficient vulvar neoplasms: report of 4 cases with review of literature
SMARCB1 (INI-1) deficient vulvar neoplasms: report of 4 cases with review of literature Open
SMARCB1 (INI-1) deficient vulvar neoplasms are rare tumors with scarce available literature. These tumors can be comprised of proximal type epithelioid sarcoma (ES), myoepithelial carcinoma (MEC), myoepithelioma-like tumor of the vulvar re…
View article: Supplementary Figure S4 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Supplementary Figure S4 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma Open
Replicate data of DNA damage assays
View article: Supplementary Fig. 2 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
Supplementary Fig. 2 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis Open
Supplementary Fig. 2
View article: Supplementary Table S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
Supplementary Table S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101) Open
Summary of response outcomes across subgroups